Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

NCT01283945 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

134

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Lucitanib

Sponsor

Institut de Recherches Internationales Servier